Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,894 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,867 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01113970 | Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 60 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04072952 | A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer(mBC) | completed | Phase 1 / Phase 2 | 219 | Arvinas Estrogen Receptor, Inc.INDUSTRY | 1 | Sep 29, 2026 |
| clinicaltrials |
| NCT03568656 | Study to Evaluate CCS1477 in Advanced Tumours | completed | Phase 1 / Phase 2 | 219 | CellCentric Ltd.INDUSTRY | 6 | Sep 25, 2026 | clinicaltrials |
| NCT02390427 | Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer | completed | Phase 1 | 68 | Nancy Lin, MDOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03455270 | G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer | completed | Phase 1 | 107 | G1 Therapeutics, Inc.INDUSTRY | 7 | Sep 21, 2026 | clinicaltrials |
| NCT04276493 | Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab | completed | Phase 1 / Phase 2 | 71 | BeiGeneINDUSTRY | 3 | Sep 2, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT01791478 | BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer | completed | Phase 1 | 46 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03096054 | A Phase I Trial of LY3143921 Hydrate in Solid Tumours | completed | Phase 1 | 69 | Cancer Research UKOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06047184 | Phase I Study of BEBT-209 in Women With Advanced Breast Cancer | completed | Phase 1 | 100 | BeBetter Med IncINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07300202 | A Phase I, Single-arm, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Orialpha (BD-C) in Healthy Adult Volunteers | completed | Phase 1 | 15 | Oriplantee Company LimitedOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT02009449 | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors(IVY) | completed | Phase 1 | 353 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06115902 | A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer | completed | Phase 1 | 153 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06745804 | Study of 68Ga-R10602 | completed | Phase 1 | 27 | Radionetics OncologyINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT00317720 | Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05064085 | Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer | completed | Phase 1 | 13 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05203497 | Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2 | completed | Phase 1 | 30 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05940298 | Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT02206334 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer | completed | Phase 1 | 42 | NRG OncologyOTHER | 3 | Jun 25, 2026 | clinicaltrials |
| NCT04277338 | Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3(HE3-G3) | completed | Phase 1 | 30 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT02792465 | A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors | completed | Phase 1 | 52 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06006299 | Investigating the Use of taVNS to Treat Insomnia in Individuals With Breast Cancer (taVNS-insomnia-BC) | completed | Phase 1 | 20 | University of Alabama at BirminghamOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04737265 | Pilot Study of an NTproBNP Guided Strategy of Cardioprotection(NTproBNP-Guide) | completed | Phase 1 / Phase 2 | 108 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07648940 | Bioequivalence Study of Liposomal Doxorubicin 20 mg/10 mL (Doxopeg® vs Caelyx®) in Advanced Cancer Patients | completed | Phase 1 | 74 | Zodiac Produtos Farmaceuticos S.A.INDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT02392845 | A Pilot Dose Escalation Trial of a Densified Chemotherapy Association of Docetaxel and Epirubicin Driven by Mathematical Modeling in Metastatic Breast Cancer Patients: The MODEL1 Study(MODEL1) | completed | Phase 1 | 17 | Hospices Civils de LyonOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06253195 | BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | completed | Phase 1 | 33 | BeOne MedicinesINDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT03289962 | A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | completed | Phase 1 | 273 | Genentech, Inc.INDUSTRY | 8 | Jun 8, 2026 | clinicaltrials |
| NCT07320521 | A Study to Assess the Mass Balance of [14C]HRS-8080 in Healthy Chinese Postmenopausal Female Subjects. | completed | Phase 1 | 6 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06570031 | ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer | completed | Phase 1 | 46 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06710990 | Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer | completed | Phase 1 | 17 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06300411 | SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery | completed | Phase 1 | 25 | SURGE TherapeuticsINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT00600496 | A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | completed | Phase 1 | 140 | AstraZenecaINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT05181462 | Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.(TRIFOUR) | completed | Phase 1 / Phase 2 | 117 | Cantargia ABINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT06619873 | A Clinical Study to Evaluate the Relative Bioavailability and Food Effect of HRS-8080 in Healthy Subjects | completed | Phase 1 | 24 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT03789097 | Vaccination With Flt3L, Radiation, and Poly-ICLC | completed | Phase 1 / Phase 2 | 17 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05900986 | LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer | completed | Phase 1 / Phase 2 | 22 | Integro TheranosticsINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT04505826 | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer | completed | Phase 1 / Phase 2 | 153 | Olema Pharmaceuticals, Inc.INDUSTRY | 2 | May 11, 2026 | clinicaltrials |
| NCT03552718 | QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. | completed | Phase 1 | 5 | NantBioScience, Inc.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT03218826 | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2026 | clinicaltrials |
| NCT00872625 | Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer | completed | Phase 1 | 26 | Centre Antoine LacassagneOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT02705859 | Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)(Panther) | completed | Phase 1 | 26 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03850873 | A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics | completed | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT00066443 | Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer | completed | Phase 1 / Phase 2 | 93 | NCIC Clinical Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03328026 | Combination Study of SV-BR-1-GM With Retifanlimab | completed | Phase 1 / Phase 2 | 36 | BriaCell Therapeutics CorporationINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05963997 | A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer(SUMIT-ELA) | completed | Phase 1 / Phase 2 | 49 | Carrick Therapeutics LimitedINDUSTRY | 4 | Mar 23, 2026 | clinicaltrials |
| NCT03709446 | Leflunomide in Previously Treated Metastatic Triple Negative Cancers | completed | Phase 1 / Phase 2 | 17 | Joseph SparanoOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03725436 | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors | completed | Phase 1 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 16, 2026 | clinicaltrials |
Data updated 21 hours agoSource updated Sep 29, 2026source: clinicaltrials